## Albert S Galyavich

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4554977/publications.pdf

Version: 2024-02-01

1170033 1051228 39 295 9 16 citations g-index h-index papers 46 46 46 194 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	ACTIV SARS-CoV-2 registry (Analysis of Chronic Non-infectious Diseases Dynamics After COVID-19) Tj ETQq1 1 with COVID-19 on the prognosis. Terapevticheskii Arkhiv, 2022, 94, 32-47.	. 0.784314 r 0 <b>.</b> 2	gBT /Overlo <mark>ck</mark> 10
2	Pharmacoepidemiological analysis of routine management of heart failure patients in the Russian Federation. Part II. Russian Journal of Cardiology, 2022, 27, 4759.	0.4	3
3	Approaches to the therapy of heart failure with reduced ejection fraction. Resolution of an online meeting of the Volga Federal District experts. Russian Journal of Cardiology, 2022, 26, 4791.	0.4	1
4	Practical guidelines for the diagnosis and treatment of transthyretin amyloid cardiomyopathy (ATTR-CM or transthyretin cardiac amyloidosis). Terapevticheskii Arkhiv, 2022, 94, 584-595.	0.2	9
5	EVALUATION OF THE EFFICIENCY OF DUAL ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME WHO UNDERWENT PERCUTANEOUS CORONARY INTERVENTION. Vrach, 2021, 32, 56-60.	0.0	0
6	EURASIAN ASSOCIATION OF CARDIOLOGY (EAC) GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (2020). Eurasian Heart Journal, 2021, , 6-43.	0.2	20
7	Expert consensus. Effect of antihypertensive therapy on cognitive functions. Systemic Hypertension, 2021, 18, 5-12.	0.1	4
8	Predictive value of growth differentiation factor-15 in patients with myocardial infarction. Russian Journal of Cardiology, 2021, 26, 4288.	0.4	3
9	Aspects of efficacy, safety and adherence to antihypertensive therapy with single pill combinations of valsartan, amlodipine and hydrochlorothiazide (Vamloset® and Co-Vamloset) in patients with 2 and 3 grade of arterial hypertension in the Russian clinical study VICTORY II. Systemic Hypertension, 2021, 18, 50-62.	0.1	0
10	Pharmacoepidemiological analysis of routine management of heart failure patients in the Russian Federation. Part I. Russian Journal of Cardiology, 2021, 26, 4368.	0.4	10
11	Visit-to-visit blood pressure variability in patients after acute coronary syndrome. Arterial Hypertension (Russian Federation), 2021, 27, 206-215.	0.1	0
12	Practical efficacy and safety of Konsilar D24 in patients with hypertension: data from the KONSONANS program. Russian Journal of Cardiology, 2021, 26, 4651.	0.4	4
13	Principles of organization of medical care for patients with heart failure in the system of cardiovascular risk management: focus on continuity of care and patient routing. Practical materials. Russian Journal of Cardiology, 2021, 26, 4558.	0.4	8
14	Empagliflozin and heart failure: position paper of the experts on the results of the online meeting and discussion of the EMPEROR-Preserved Trial. Terapevticheskii Arkhiv, 2021, 93, 1491-1497.	0.2	6
15	The Fight Against CVD in a Region of the Russian Federation. Global Heart, 2020, 11, 445.	0.9	0
16	Emergency care in a sudden individually significant blood pressure increase without clinically overt target organ damage: rationale for captopril use. Expert Council opinion. Russian Journal of Cardiology, 2020, 25, 103-110.	0.4	5
17	Modern antihypertensive therapy: the effectiveness of a unique Russian fixed-dose combination of ramipril and indapamide. Russian Journal of Cardiology, 2020, 25, 3782.	0.4	6
18	Discussion of a new classification for coronary artery disease. Russian Journal of Cardiology, 2020, 25, 111-112.	0.4	1

#	Article	IF	CITATIONS
19	Outcomes in patients with hypertension and type 2 diabetes receiving a stent for angina. Russian Journal of Cardiology, 2020, 25, 3800.	0.4	1
20	Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement. Russian Journal of Cardiology, 2020, 25, 3919.	0.4	3
21	Long-term mortality risk in hospitalized patients with heart failure after myocardial infarction. Russian Journal of Cardiology, 2020, 25, 14-18.	0.4	O
22	Vasospastic angina — vasospastic myocardial infarction. Russian Journal of Cardiology, 2020, 25, 98-99.	0.4	0
23	Levels of proprotein convertase subtilisin/kexin type 9 in patients with acute myocardial infarction. Russian Journal of Cardiology, 2020, 25, 42-44.	0.4	0
24	Clinical outcomes in hypertension patients after coronary stenting due to exertional angina. Russian Journal of Cardiology, 2020, 25, 3736.	0.4	0
25	Bleeding risk scales in patients with acute coronary syndrome: place of the ORACUL scale. Cardiovascular Therapy and Prevention (Russian Federation), 2020, 19, 2333.	0.4	0
26	Abstract 14556: Is There a Relationship Between Lipoprotein (a) and Proprotein Convertase Subtilisin /keksin Type 9 and Cardiovascular Events After Acute Myocardial Infarction?. Circulation, 2020, 142, .	1.6	0
27	Place of Prasugrel, P2Y12 receptor antagonist, in an early invasive treatment of patients with acute coronary syndrome (according to the results of multicenter randomized controlled trial ISAR-REACT) Tj ETQq1 1	0.78 <b>4</b> 314	∤rgBT /Over
28	Risk factors of coronary artery disease in 27425 outpatients. Russian Journal of Cardiology, 2019, , 23-26.	0.4	9
29	Differentiated approach in diagnostics, diagnosis formulation, case management and statistical accounting of type 2 myocardial infarction (Position Paper). Russian Journal of Cardiology, 2019, , 7-21.	0.4	15
30	The predictive value of preprocedural laboratory data in patients with coronary artery restenosis in various types of stents. Russian Journal of Cardiology, 2019, 24, 54-59.	0.4	1
31	Myocardial infarction and Turner syndrome. Russian Journal of Cardiology, 2019, 24, 98-100.	0.4	0
32	Russian Society of Cardiology position paper on 2018 Guidelines of the European Society of Cardiology/European Society of Arterial Hypertension for the management of arterial hypertension. Russian Journal of Cardiology, 2018, , 131-142.	0.4	35
33	Targeted sequencing in patients with clinically diagnosed hereditary lipid metabolism disorder and acute coronary syndrome. Bulletin of Russian State Medical University, 2018, , 80-86.	0.3	7
34	Gender differences in the course of myocardial infarction. Neotloå¾naâ Kardiologiâ, 2018, , 35-40.	0.1	1
35	Polymorphism of TNF gene in acute coronary syndrome patients: data from the registries ORACLE I and ORACLE II. Russian Journal of Cardiology, 2018, , 22-27.	0.4	1
36	Selection of antihypertensive therapy in elderly patients, combination therapy: thiazide-like diuretics and calcium channel blockers. Russian Journal of Cardiology, 2018, , 117-122.	0.4	0

#	Article	IF	CITATIONS
37	The management of acute myocardial infarction in the Russian Federation: protocol for a study of patient pathways. Wellcome Open Research, 2017, 2, 89.	0.9	3
38	Identification and Management of Patients With Hypertension in the Polyclinic System of the Russian Federation. American Journal of Hypertension, 2005, 18, 943-948.	1.0	10
39	Quality of Life and Compliance with Treatment in Patients with Essential Hypertension. Kazan Medical Journal, 2001, 82, 198-202.	0.1	7